Blog
About

4
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Major bleeding risk and healthcare economic outcomes of non-valvular atrial fibrillation patients newly-initiated with oral anticoagulant therapy in the real-world setting.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          This study compared the risk for major bleeding (MB) and healthcare economic outcomes of patients with non-valvular atrial fibrillation (NVAF) after initiating treatment with apixaban vs rivaroxaban, dabigatran, or warfarin.

          Related collections

          Author and article information

          Journal
          J Med Econ
          Journal of medical economics
          Informa UK Limited
          1941-837X
          1369-6998
          Sep 2017
          : 20
          : 9
          Affiliations
          [1 ] a Novosys Health , Green Brook , NJ , USA.
          [2 ] b Pfizer, Inc. , New York , NY , USA.
          [3 ] c Bristol-Myers Squibb , Lawrenceville , NJ , USA.
          Article
          10.1080/13696998.2017.1341902
          28604139

          Comments

          Comment on this article